DOI: 10.4103/mjbl.mjbl_1209_23 ISSN: 1812-156X

Investigation of Gene Expression of RUNX1 and RUNX3 in Acute Leukemia Patients

Maytham A.M. Alkaby, Maytham A. Dragh
Show PDF Cite

Abstract

Background:

RUNX1 and RUNX3 are important genes associated with leukemia, given that mutations in these genes have been connected to myeloid malignancy and hereditary platelet disease.

Objective:

By comparing the levels of expression of the aforementioned genes in the two groups, gene expression analysis can provide light on these genes’ potential roles such as tumor suppressors or oncogenes in cancer.

Materials and Methods:

The investigated group consisted of 40 patients, with 20 diagnosed with acute myeloid leukemia (AML) and 20 diagnosed with acute lymphoblastic leukemia (ALL). The age range of the patients was between 14 and 80 years. A control group of 20 voluntary blood donors was included.

Results:

The RUNX1 gene’s expression was shown to be significantly different between AML patients and healthy people. However, there were no significant variations in RUNX1 expression between ALL patients and healthy people. However, neither the expression of the RUNX3 gene in AML nor ALL patients was substantially different from that of healthy individuals.

Conclusion:

These results show that RUNX1 may act as an oncogene in AML. Moreover, the expression of RUNX3 in both AML and ALL cases indicates its potential involvement as a tumor suppressor in different leukemia subtypes.

More from our Archive